GeoVax Labs’ (GOVX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a research note published on Tuesday morning, Benzinga reports. They currently have a $8.00 price objective on the stock.

GeoVax Labs Price Performance

NASDAQ GOVX opened at $2.80 on Tuesday. The stock’s fifty day moving average price is $1.91 and its 200 day moving average price is $2.68. GeoVax Labs has a 1 year low of $1.09 and a 1 year high of $10.24.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($2.47) earnings per share for the quarter. Sell-side analysts forecast that GeoVax Labs will post -7.41 EPS for the current fiscal year.

Institutional Trading of GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Armistice Capital LLC acquired a new stake in GeoVax Labs, Inc. (NASDAQ:GOVX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned 91.38% of GeoVax Labs as of its most recent SEC filing. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.